Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 13

Opinion

Video

July 24, 2024

Multiple Sclerosis: Looking Toward the Future

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Heidi Crayton, MD

Heidi Crayton, MD, and Maria Lopes, MD, discuss future research in multiple sclerosis that they find exciting and promising.

EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

EP: 4.Examining Key Unmet Needs in Multiple Sclerosis

EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment

EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

Now Viewing

EP: 13.Multiple Sclerosis: Looking Toward the Future

Video content above is prompted by the following question:

Are there any areas of future research in multiple sclerosis (MS) that you are excited for?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com

April 9th 2025

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

Rose McNulty

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

November 30th 2021

Millennials With Multiple Sclerosis: Are They Different or Has Medicine Evolved?

On this episode of Managed Care Cast, hear from a multiple sclerosis (MS) specialist about how millennial patients are different (or not) in how they approach their disease.

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg

March 12th 2025

Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

Christina Mattina Kavita V. Nair, PhD

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming care in their area of expertise. This issue spotlights a conversation with Kavita V. Nair, PhD, of the University of Colorado Anschutz Medical Campus.

December 1st 2019

Podcast: This Week in Managed Care—Challenges of Rural Healthcare Delivery and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

Ocrelizumab is a monoclonal antibody that targets CD20 on B cells | image credit: molekuul.be - stock.adobe.com

January 8th 2025

Subcutaneous Ocrelizumab Well Tolerated in Patients With MS

Karen Jacobson-Sive

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS).

Patients with MS had higher odds of filling prescriptions for anticonvulsants and higher odds of filling gabapentinoids and gabapentinoids without other anticonvulsants in the years leading up to onset of MS. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

January 6th 2025

Pain May Be Indicator of MS Prior to Disease Onset: Study

AJMC Contributor

Compared with healthy controls, patients with multiple sclerosis (MS) had higher odds of filling prescriptions for gabapentinoids and other anticonvulsants in the 5 years prior to MS onset.